πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

63 results for β€œinhalation” Clear

  1. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Placebo MDI HFA to match BGF MDI HFA, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)

    phase 3 small molecule active

    1 trial

  2. epinephrine inhalation aerosol

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule completed

    2 trials

  3. 0.9% Sodium chloride - inhalation solution

    Arrowhead Pharmaceuticals Ireland Limited

    Inflammatory Lung Disease

    phase 2 small molecule active

    1 trial

  4. 0.9% sodium chloride - inhalation solution, ARO-MUC5AC Inhalation Solution

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma and Chronic obstructive pulmonary disease

    phase 2 small molecule active

    1 trial

  5. ARO-MMP7 Inhalation Solution

    Arrowhead Pharmaceuticals Ireland Limited

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  6. Amikacin inhalation solution (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia

    phase 2 small molecule completed

    1 trial

  7. Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule terminated

    1 trial

  8. CHF5993 pMDI (100) -152a, CHF5993 pMDI HFA-152a, Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution

    Chiesi Farmaceutici S.p.A

    Mild to moderate asthma

    phase 2 small molecule active

    1 trial

  9. E004 (epinephrine inhalation aerosol), 90 mcg/actuation

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule terminated

    1 trial

  10. Epinephrine Inhalation Aerosol, HFA

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule completed

    1 trial

  11. Lucinactant for Inhalation

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome, Newborn

    phase 2 other terminated

    1 trial

  12. Lucinactant for inhalation

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome

    phase 2 other terminated

    2 trials

  13. Mebufotenin, Mebufotenin, Inhalation vapour, liquid, Mebufotenin

    Elan Pharma International

    Treatment-resistant depression (TRD)

    phase 2 small molecule active

    1 trial

  14. PUL-042 Inhalation Solution

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 small molecule completed

    2 trials

  15. Pirfenidone Solution for Inhalation

    Lacuna Pharma Pty Ltd

    Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  16. Pirfenidone Solution for Inhalation

    Lacuna Pharma Pty Ltd

    Progressive pulmonary fibrosis [PPF] Idiopathic pulmonary fibrosis [IPF]

    phase 2 small molecule active

    1 trial

  17. Pirfenidone Solution for Inhalation, Pirfenidone Solution for Inhalation, Placebo for AP01

    Lacuna Pharma Pty Ltd

    Progressive Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  18. Revefenacin Inhalation Solution [Yupelri]

    Theravance Biopharma Ireland Umited

    COPD

    phase 2 small molecule completed

    1 trial

  19. SALBUTAMOL, FLUTICASONE PROPIONATE, NVA237, NVA237, SALMETEROL XINAFOATE, The Placebo is a generic Placebo, inhalation powder, hard capsule. It is used to match an active dosage forms (NVA237 12.5Β΅g and NVA 237 25Β΅g) in this clinical trial. The placebo comprises inactive excipients (magnesium stearate and lactose monohydrate) encapsulated in hard non-gelatin capsules matching those used for the active drug product.

    Novartis Pharmaceuticals

    Asthma

    phase 2 small molecule active

    1 trial

  20. TREPROSTINIL PALMITIL INHALATION POWDER, Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 ΞΌg, 160 ΞΌg, or 320 ΞΌg), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial

  21. The placebo is the same as the ensifentrine suspension except that the active ensifentrine ingredient is omitted (i.e., it consists of phosphate buffered saline and surfactants only); it is also supplied as a single unit-dose LDPE translucent ampule overwrapped in a foil pouch, Ensifentrine inhalation suspension

    Lacuna Pharma Pty Ltd

    Non-Cystic Fibrosis Bronchiectasis

    phase 2 small molecule active

    1 trial

  22. Treprostinil Inhalation Solution

    United Therapeutics Europe Ltd

    Respiratory Distress Syndrome, Adult

    phase 2 small molecule terminated

    1 trial

  23. albuterol inhalation powder

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule completed

    1 trial

  24. A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists

    AstraZeneca AB

    Asthma

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources